In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application

Journal of Controlled Release

Volumn 170, Issue 1, 2013, Pages 153-159

  Rodriguez Aller, Marta ^a   Guillarme, Davy ^a   El Sanharawi, Mohamed ^b   Behar Cohen, Francine ^b   Veuthey, Jean Luc ^a   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Cyclosporine A; Ex vivo permeation; Eye; In vivo distribution; Prodrug; Water formulation

Indexed keywords

DROPS; PATIENT TREATMENT;

CYCLOSPORINE A; EQUIVALENT CONCENTRATIONS; EX-VIVO; IMMUNOSUPPRESSIVE DRUGS; IN-VIVO; PERMEATION EXPERIMENTS; PRODRUGS; TOPICAL APPLICATION;

DRUG PRODUCTS;

CYCLOSPORIN A; EYE DROPS; PRODRUG;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; BLOOD SAMPLING; CERVICAL LYMPH NODE; CONJUNCTIVA EPITHELIUM; CORNEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG TISSUE LEVEL; EX VIVO STUDY; FEMALE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA; SPLEEN; VITREOUS BODY;

EID: 84879051472     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.04.019     Document Type: Article

References (48)

1. T. Loftsson, M.E. Brewster, Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes, J. Pharm. Pharmacol. 63 (2011) 1119-1135.
2. F. Lallemand, P. Perottet, O. Felt-Baeyens, W. Kloeti, F. Philippoz, J. Marfurt, K. Besseghir, R. Gurny, A water-soluble prodrug of cyclosporine A for ocular application: a stability study, Eur. J. Pharm. Sci. 26 (2005) 124-129. (Pubitemid 41097269)
3. C.A. Utine, M. Stern, E.K. Akpek, Clinical review: topical ophthalmic use of cyclosporin A, Ocul. Immunol. Inflamm. 18 (2010) 352-361.
4. E. Donnenfeld, S.C. Pflugfelder, Topical ophthalmic cyclosporine: pharmacology and clinical uses, Surv. Ophthalmol. 54 (2009) 321-338.
5. W. Vine, L.D. Bowers, Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring, Crit. Rev. Clin. Lab. Sci. 25 (1987) 275-311.
6. A.G. Palestine, R.B. Nussenblatt, C.C. Chan, Side effects of systemic cyclosporine in patients not undergoing transplantation, Am. J. Med. 77 (1984) 652-656. (Pubitemid 14047594)
7. C.A. Le Bourlais, F. Chevanne, B. Turlin, L. Acar, H. Zia, P.A. Sado, T.E. Needham, R. Leverge, Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study, J. Microencapsul. 14 (1997) 457-467. (Pubitemid 27313368)
8. P. Versura, M. Cellini, P.G. Zucchini, R. Caramazza, R. Laschi, Ultrastructural and immunohistochemical study on the effect of topical cyclosporin A in the rabbit eye, Cornea 8 (1989) 81-89. (Pubitemid 19167702)
9. J.M. Benitez del Castillo, C. del Aguila, S. Duran, J. Hernandez, J. Garcia Sanchez, Influence of topically applied cyclosporine A in olive oil on corneal epithelium permeability, Cornea 13 (1994) 136-140. (Pubitemid 24083050)
10. L. Goichot-Bonnat, P. Chemla, Y. Pouliquen, Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results, J. Fr. Ophtalmol. 10 (1987) 213-217.
11. D.L. Williams, A comparative approach to topical cyclosporine therapy, Eye 11 (Pt. 4) (1997) 453-464. (Pubitemid 27434976)
12. M. Kuwano, H. Ibuki, N. Morikawa, A. Ota, Y. Kawashima, Cyclosporine A formulation affects its ocular distribution in rabbits, Pharm. Res. 19 (2002) 108-111. (Pubitemid 34075115)
13. M. Diaz-Llopis, J.L. Menezo, Penetration of 2% cyclosporin eyedrops into human aqueous humour, Br. J. Ophthalmol. 73 (1989) 600-603. (Pubitemid 19202065)
14. L. Cheeks, R.L. Kaswan, K. Green, Influence of vehicle and anterior chamber protein concentration on cyclosporine penetration through the isolated rabbit cornea, Curr. Eye Res. 11 (1992) 641-649.
15. A.R. Hamel, F. Hubler, M. Mutter, Water-soluble prodrugs of cyclosporine A with tailored conversion rates, J. Pept. Res. 65 (2005) 364-374. (Pubitemid 40477011)
16. F. Lallemand, O. Felt-Baeyens, S. Rudaz, A.R. Hamel, F. Hubler, R. Wenger, M. Mutter, K. Besseghir, R. Gurny, Conversion of cyclosporine A prodrugs in human tears vs rabbits tears, Eur. J. Pharm. Biopharm. 59 (2005) 51-56. (Pubitemid 39573436)
17. F. Lallemand, P. Furrer, O. Felt-Baeyens, M. Gex-Fabry, J.M. Dumont, K. Besseghir, R. Gurny, A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics, Int. J. Pharm. 295 (2005) 7-14. (Pubitemid 40558784)
18. F. Lallemand, E. Varesio, O. Felt-Baeyens, L. Bossy, G. Hopfgartner, R. Gurny, Biological conversion of a water-soluble prodrug of cyclosporine A, Eur. J. Pharm. Biopharm. 67 (2007) 555-561. (Pubitemid 47211915)
19. M. Rodriguez-Aller, B. Kaufmann, D. Guillarme, C. Stella, P. Furrer, S. Rudaz, I. El Zaoui, F. Valamanesh, C. Di Tommaso, F. Behar-Cohen, J.L. Veuthey, R. Gurny, In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease, Eur. J. Pharm. Biopharm. 80 (2012) 544-552.
20. E. Clarke, Clarke's Isolation and Identification of Drugs, 2nd ed. Pharmaceutical Press, London, 1986.
21. H. Nourry, S. Perrot, C. Martin, C. Chaumeil, C. Cambourieu, P. Rat, J.M. Warnet, Cytotoxicity evaluation of different eyes drops with cyclosporine oral solution (Sandimmun), J. Fr. Ophtalmol. 29 (2006) 251-257.
22. M.A. Redell, D.C. Yang, V.H.L. Lee, The role of esterase-activity in the ocular disposition of dipivalyl epinephrine in rabbits, Int. J. Pharm. 17 (1983) 299-312. (Pubitemid 14209375)
23. V.H. Lee, K.W. Morimoto, R.E. Stratford Jr., Esterase distribution in the rabbit cornea and its implications in ocular drug bioavailability, Biopharm. Drug Dispos. 3 (1982) 291-300. (Pubitemid 13217252)
24. R.D. Schoenwald, H.S. Huang, Corneal penetration behavior of β-blocking agents I: Physiochemical factors, J. Pharm. Sci. 72 (1983) 1266-1272. (Pubitemid 14229733)
25. K. Jarvinen, T. Jarvinen, A. Urtti, Ocular absorption following topical delivery, Adv. Drug Deliv. Rev. 16 (1995) 3-19.
26. R.W. Massof, F.W. Chang, A revision of the rat schematic eye, Vision Res. 12 (1972) 793-796.
27. B.Leblanc,S. Jezequel, T. Davies,G.Hanton, C. Taradach,Bindingof drugs toeyemelanin is not predictive of ocular toxicity, Regul. Toxicol. Pharmacol. 28 (1998) 124-132. (Pubitemid 29076778)
28. R. Gaudana, H.K. Ananthula, A. Parenky, A.K. Mitra, Ocular drug delivery, AAPS J. 12 (2010) 348-360.
29. D.H. Geroski, H.F. Edelhauser, Transscleral drug delivery for posterior segment disease, Adv. Drug Deliv. Rev. 52 (2001) 37-48. (Pubitemid 32973637)
30. A. Urtti, Challenges and obstacles of ocular pharmacokinetics and drug delivery, Adv. Drug Deliv. Rev. 58 (2006) 1131-1135.
31. K.M. Hamalainen, K. Kananen, S. Auriola, K. Kontturi, A. Urtti, Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera, Invest. Ophthalmol. Vis. Sci. 38 (1997) 627-634. (Pubitemid 27143133)
32. M.A. Watsky, M.M. Jablonski, H.F. Edelhauser, Comparison of conjunctival and corneal surface areas in rabbit and human, Curr. Eye Res. 7 (1988) 483-486.
33. M.R. Prausnitz, J.S. Noonan, Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye, J. Pharm. Sci. 87 (1998) 1479-1488.
34. A. Tsuji, I. Tamai, K. Sasaki, Hydrolysis of prednisolone succinate by esterase in rabbit ocular tissue, Ophthalmic Res. 19 (1987) 322-329. (Pubitemid 18029347)
35. V.H. Lee, D.S. Iimoto, K.A. Takemoto, Subcellular distribution of esterases in the bovine eye, Curr. Eye Res. 2 (1982) 869-876. (Pubitemid 14210128)
36. V.H. Lee, S.C. Chang, C.M. Oshiro, R.E. Smith, Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation, Curr. Eye Res. 4 (1985) 1117-1125. (Pubitemid 16254493)
37. B. Nichols, C.R. Dawson, B. Togni, Surface features of the conjunctiva and cornea, Invest. Ophthalmol. Vis. Sci. 24 (1983) 570-576. (Pubitemid 13096971)
38. D. BenEzra, G. Maftzir, Ocular penetration of cyclosporine A in the rat eye, Arch. Ophthalmol. 108 (1990) 584-587. (Pubitemid 20142544)
39. D. BenEzra, G. Maftzir, Ocular penetration of cyclosporin A. The rabbit eye, Invest. Ophthalmol. Vis. Sci. 31 (1990) 1362-1366. (Pubitemid 20212368)
40. D. BenEzra, G. Maftzir, C. de Courten, P. Timonen, Ocular penetration of cyclosporin A. III: the human eye, Br. J. Ophthalmol. 74 (1990) 350-352. (Pubitemid 20191167)
41. A.A. Acheampong, M. Shackleton, D.D. Tang-Liu, S. Ding, M.E. Stern, R. Decker, Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs, Curr. Eye Res. 18 (1999) 91-103. (Pubitemid 29137565)
42. L. Gan, Y. Gan, C. Zhu, X. Zhang, J. Zhu, Novel microemulsion in situ electrolytetriggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results, Int. J. Pharm. 365 (2009) 143-149.
43. J. Shen, Y. Deng, X. Jin, Q. Ping, Z. Su, L. Li, Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution, Int. J. Pharm. 402 (2010) 248-253.
44. M. Wiederholt, D. Kossendrup, W. Schulz, F. Hoffmann, Pharmacokinetic of topical cyclosporin A in the rabbit eye, Invest. Ophthalmol. Vis. Sci. 27 (1986) 519-524. (Pubitemid 16116297)
45. N. Maziers, P. Bulpa, J. Jamart, L. Delaunois, P. Eucher, P. Evrard, Correlations between cyclosporine concentrations at 2 hours post-dose and trough levels with functional outcomes in de novo lung transplant recipients, Transplant. Proc. 44 (2012) 2880-2884.
46. P. Cugini,M. Cavallini, P. Pozzilli, C. Letizia, M. Sepe, L. Di Palma, P. Battisti, Circadian rhythm of T-lymphocyte subsets, cortisol and cyclosporin in kidney-transplanted subjects, Nephrol. Dial. Transplant. 6 (1991) 512-517.
47. K.J. Lafferty, J.F. Borel, P. Hodgkin, Cyclosporine-a (Csa) -models for the mechanism of action, Transplant. Proc. 15 (1983) 2242-2247. (Pubitemid 14162229)
48. R.L. Kaswan, Intraocular penetration of topically applied cyclosporine, Transplant. Proc. 20 (1988) 650-655.